Given that the MAPK/ERK/ELK1 axis regulates BCL6 expression, we additionally explored whether BCL6 pharmacological inhibitors, such as COMP7, in combination with MEKi, could lead to more potent tumor inhibition than single-agent treatment. Here, ELK1 is linked to neoplasm.